Two major treatment strategies in non-small cell lung cancer (NSCLC) are tyrosine kinase inhibitors & immune checkpoint inhibitors. Strategy choice is based on heterogeneous biomarkers expressed by lung tumor tissue. Moffitt’s diagnostic technology provides a rapid and non-invasive method for precise quantification of EGFR mutation & PD-L1 status in NSCLC patients and predicts appropriate treatment regimens.
Contact:
Praba Soundararajan, PhD
praba.soundararajan@moffitt.org
